Avid Bioservices Inc (CDMO)

[Thurly]

Yes.

TUSTIN, CA -- (MARKET WIRE) -- 01/05/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated stage IV pancreatic cancer.

TUSTIN, CA -- (Marketwire) -- 06/25/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the completion of enrollment and randomization of 70 patients in a Phase II trial evaluating bavituximab in combination with gemcitabine versus gemcitabine alone in patients with previously untreated stage IV pancreatic cancer.